drugset / Trial / NCT04639739
Anti-CD19 CAR NK Cell Therapy for R/R Non-Hodgkin Lymphoma.
Phase 0
Unknown
9 enrolled
Xinqiao Hospital of Chongqing
Chongqing Precision Biotech Co., Ltd · collab
NaSingle-groupOpen-labelTreatment
Summary
Although the anti-CD19 CAR-T cell therapies have gained significant results in patients with relapsed and refractory B-cell hematologic malignancies. There are limitations of CAR-T cells, the consuming manufacturing time and expensive price exclude the majority of patients. therefore, we designed this trial to manifest the safety and efficacy of anti-CD19 CAR NK cell therapy in non-Hodgkin lymphoma
Timeline
- Start
- 2020-12-17
- Primary completion
- 2021-12-01
- Completion
- 2023-12-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | anti-CD19 CAR-NK | Cell therapy | 2e+06 cells/kg | — |
| Subject | anti-CD19 CAR-NK | Cell therapy | 6e+06 cells/kg | — |
| Subject | anti-CD19 CAR-NK | Cell therapy | 2e+07 cells/kg | — |
| Background | Cyclophosphamide | Other / unclassified | 500 mg/m2 | — |
| Background | Fludarabine | Small molecule | 30 mg/m2 | — |